Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.39 |
| ▸ | TUBB | P07437 | 2/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.39 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132329 | 1.00 | PTGS2 (0.41) | PTGS2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1771821 | 0.97 | PTGS2 (0.41) | PTGS2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4964426 | 0.81 | ERN1 (0.43) | — | |
| SCHEMBL4289238 | 0.80 | PTGS2 (0.53) | PTGS2 | |
| SCHEMBL1771769 | 0.79 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1771766 | 0.79 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4127426 | 0.78 | PTGS2 (0.39) | PTGS2 | |
| SCHEMBL1772485 | 0.76 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1771491 | 0.73 | TUBB4A (0.42) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1771493 | 0.73 | TUBB4A (0.42) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896391-B1 | COMBRETASTATIN ANALOGS WITH TUBULIN BINDING ACTIVITY | UNIV BAYLOR (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8394859-B2 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394859-B2 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394859-B2 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY (US) | 2013-03-12 | — | — | US | disclosed |
| US-20090075943-A1 | Combretastatin Analogs with Tubulin Binding Activity | BAYLOR UNIVERSITY | 2009-03-19 | — | — | US | disclosed |
| US-20090075943-A1 | Combretastatin Analogs with Tubulin Binding Activity | BAYLOR UNIVERSITY | 2009-03-19 | — | — | US | disclosed |
| US-20090075943-A1 | Combretastatin Analogs with Tubulin Binding Activity | BAYLOR UNIVERSITY | 2009-03-19 | — | — | US | disclosed |
| US-7429681-B2 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429681-B2 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429681-B2 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1896391-A2 | COMBRETASTATIN ANALOGS WITH TUBULIN BINDING ACTIVITY | Baylor University (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20060293394-A1 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY | 2006-12-28 | — | — | US | disclosed |
| WO-2006138427-A2 | COMBRETASTATIN ANALOGS WITH TUBULIN BINDING ACTIVITY | BAYLOR UNIVERSITY (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293394-A1 | Combretastatin analogs with tubulin binding activity | TUBB, TUBB3, TUBB1 | PTGS2 3482/4885TUBB4A 5/4885TUBB 1/4885 |
| US-20090075943-A1 | Combretastatin Analogs with Tubulin Binding Activity | TUBB, TUBB3, TUBB1 | PTGS2 3482/4885TUBB4A 5/4885TUBB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.